Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

This retrospective analysis conducted using data from patients enrolled onto the Herceptin Adjuvant has two objectives: The first is to evaluate the impact of the time interval between the end of adjuvant trastuzumab and distant recurrence (TDRI) upon overall survival (OS). The second is to describe...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Breast Cancer Res Treat
Autori principali: Metzger-Filho, Otto, de Azambuja, Evandro, Procter, Marion, Krieguer, Magalie, Smith, Ian, Baselga, Jose, Cameron, David, Untch, Michael, Jackisch, Christian, Bell, Richard, Gianni, Luca, Goldhirsch, Aron, Piccart, Martine, Gelber, Richard D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4947530/
https://ncbi.nlm.nih.gov/pubmed/26708471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3656-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi